{
  "source": "PA-Med-Nec-Harvoni.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2052-17\nProgram Prior Authorization/Medical Necessity\nMedication Harvoni® (ledipasvir/sofosbuvir)\nP&T Approval Date 4/2015, 8/2015, 11/2015, 8/2016, 12/2016, 9/2017, 11/2017, 6/2019,\n3/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nHarvoni® (ledipasvir/sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus\n(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor,\nand is indicated for the treatment of chronic HCV in adults and pediatric patients 3 years of age\nand older:\n• Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis\n• Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin\n• Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with\ncompensated cirrhosis, in combination with ribavirin.\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1 infection in treatment-naïve patients\nwithout cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL, Harvoni will\nbe approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient is treatment-naive [patient has not experienced treatment failure (defined as viral\nrelapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon\nplus ribavirin or peginterferon plus ribavirin plus an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) or Sovaldi (sofosbuvir)]\n-AND-\n3. Submission of laboratory report documenting a pre-treatment HCV RNA less than 6\nmillion IU/mL\n-AND-\n4. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\n© 2025 UnitedHealthcare Services, Inc.\n1\nagent [e.g., Sovaldi (sofosbuvir)",
    "re to the treatment regimen\n-AND-\n5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\n© 2025 UnitedHealthcare Services, Inc.\n1\nagent [e.g., Sovaldi (sofosbuvir)]\nAuthorization will be issued for 8 weeks.\nB. For the treatment of chronic hepatitis C genotype 1 infection in treatment-naïve patients who\nare without cirrhosis and have a pre-treatment HCV RNA equal to or greater than 6 million\nIU/mL OR have compensated cirrhosis regardless of pre-treatment HCV RNA level, Harvoni\nwill be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient is treatment-naive [patient has not experienced treatment failure (defined as viral\nrelapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon\nplus ribavirin or peginterferon plus ribavirin plus an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) or Sovaldi (sofosbuvir)]\n-AND-\n3. One of the following:\na. Both of the following:\ni. Patient is without cirrhosis\n-AND-\nii. Submission of laboratory report documenting a pre-treatment HCV RNA equal to\nor greater than 6 million IU/mL\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n6. One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 12 weeks.\nC. For the treatment of chronic hepatitis C genotype 1 infection in treatment-naïve OR treatment-\nexperienced patients with decompensated cirrhosis, Harvoni will be approved based on all of\nthe following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. ",
    "ïve OR treatment-\nexperienced patients with decompensated cirrhosis, Harvoni will be approved based on all of\nthe following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. One of the following:\na. Patient is treatment-naive [patient has not experienced treatment failure (defined as\nviral relapse, breakthrough while on therapy, or non-responder to therapy) with\npeginterferon plus ribavirin or peginterferon plus ribavirin plus an HCV protease\ninhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)]\n-OR-\nb. Patient has experienced treatment failure, defined as viral relapse/breakthrough while\non therapy or non-responder to therapy, with a previous treatment regimen that\nincluded peginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) plus peginterferon plus ribavirin or Sovaldi (sofosbuvir)\n-AND-\n3. Both of the following:\na. Patient has decompensated liver disease (Child-Pugh B or C)\n-AND-\nb. Used in combination with ribavirin\n-AND-\n4. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\n© 2025 UnitedHealthcare Services, Inc.\n3\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n6. One of the following:\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 12 weeks.\nD. For the treatment of chronic hepatitis C genotype 1 infection in treatment-experienced patients\nwithout cirrhosis, Harvoni will be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has experienced treatment failure, defined as viral relapse/breakthrough while on\ntherapy or non-responder to therapy, with a previous treatment regimen that included\npeginterferon plus ribavirin or an HCV protease inhibitor (e.g.,",
    "re, defined as viral relapse/breakthrough while on\ntherapy or non-responder to therapy, with a previous treatment regimen that included\npeginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek, Olysio, Victrelis)\nplus peginterferon plus ribavirin or Sovaldi (sofosbuvir)\n-AND-\n3. Patient is without cirrhosis\n-AND-\n4. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n6. One of the following:\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\n© 2025 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 weeks.\nE. For the treatment of chronic hepatitis C genotype 1 infection in treatment-experienced patients\nwith compensated cirrhosis, Harvoni will be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has experienced treatment failure, defined as viral relapse/breakthrough while on\ntherapy or non-responder to therapy, with a previous treatment regimen that included\npeginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek, Olysio, Victrelis)\nplus peginterferon plus ribavirin or Sovaldi (sofosbuvir)\n-AND-\n3. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n6. One of the following:\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 24 weeks.\nF. For the treatment of chronic hepatitis C genotype 1 or 4 infection in treatment",
    "ication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 24 weeks.\nF. For the treatment of chronic hepatitis C genotype 1 or 4 infection in treatment-naïve and\ntreatment-experienced liver transplant recipients who are without cirrhosis or have\ncompensated cirrhosis, Harvoni will be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 or 4 infection\n© 2025 UnitedHealthcare Services, Inc.\n5\n-AND-\n2. One of the following:\na. Patient is treatment-naive [patient has not experienced treatment failure (defined as\nviral relapse, breakthrough while on therapy, or non-responder to therapy) with\npeginterferon plus ribavirin or peginterferon plus ribavirin plus an HCV protease\ninhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)]\n-OR-\nb. Patient has experienced treatment failure, defined as viral relapse/breakthrough while\non therapy or non-responder to therapy, with a previous treatment regimen that\nincluded peginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek,\nOlysio, Victrelis) plus peginterferon plus ribavirin or Sovaldi (sofosbuvir)\n-AND-\n3. Both of the following:\na. Patient has received a liver transplant\n-AND-\nb. Used in combination with ribavirin\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n6. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n6\n7. One of the following:\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 12 weeks.\nG. For the treatment of chronic hepatitis C genotype 4, 5 or 6 infection in treatment-naïve o",
    "Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 12 weeks.\nG. For the treatment of chronic hepatitis C genotype 4, 5 or 6 infection in treatment-naïve or\ntreatment-experienced patients who are without cirrhosis or have compensated cirrhosis,\nHarvoni will be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 4, 5 or 6 infection\n-AND-\n2. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n3. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n4. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n5. One of the following:\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 12 weeks.\n© 2025 UnitedHealthcare Services, Inc.\n7\nH. For the treatment of chronic hepatitis C genotype 1, 4, 5, or 6 infection in treatment-naïve and\nnon-direct acting antiviral treatment-experienced kidney transplant recipients who are without\ncirrhosis or have compensated cirrhosis, Harvoni will be approved based on all of the\nfollowing criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 4, 5, or 6 infection\n-AND-\n2. One of the following:\na. Patient is treatment-naive [patient has not experienced treatment failure (defined as\nviral relapse, breakthrough while on therapy, or nonresponder to therapy) with\npeginterferon plus ribavirin or peginterferon plus ribavirin plus an HCV protease\ninhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)]\n-OR-\nb. Patient has not been previously treated with a direct acting antiviral [e.g., Sovaldi\n(sofosbuvir)]\n-AND-\n3. Patient has received a kidney transplant\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has co",
    "ated with a direct acting antiviral [e.g., Sovaldi\n(sofosbuvir)]\n-AND-\n3. Patient has received a kidney transplant\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n6. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n© 2025 UnitedHealthcare Services, Inc.\n8\n-AND-\n7. One of the following:\na. History of intolerance or contraindication to Epclusa therapy\n-OR-\nb. Patient is currently on Harvoni therapy\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply Limits may be in place.\n4. References:\n1. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; December 2024.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttp://www.hcvguidelines.org/full-report-view. Accessed April 9, 2025.\nProgram Prior Authorization/Medical Necessity - Harvoni (ledipasvir/sofosbuvir)\nChange Control\n4/2015 Coverage requirements for State of New Jersey effective 5/18/2015.\n8/2015 Added criteria for genotype 4 infection\n11/2015 Changed program title to include all lines of business, added genotypes 5\nand 6, and updated language regarding documentation of liver fibrosis.\n8/20",
    "15 Added criteria for genotype 4 infection\n11/2015 Changed program title to include all lines of business, added genotypes 5\nand 6, and updated language regarding documentation of liver fibrosis.\n8/2016 Revised treatment-experienced with cirrhosis criteria to include ribavirin\nand Epclusa.\n11/2016 Added California coverage information.\n12/2016 Removed abstinence-based criteria and replaced with treatment readiness\nscreening criteria. Added Maryland, Indiana and West Virginia coverage\ninformation.\n5/2017 Administrative update to reorder criteria. State mandate reference\nlanguage updated.\n5/2017 Administrative update to correct formatting.\n9/2017 Revised step therapy criteria based on new product availability, included\nNY prescriber requirement, removed treatment readiness screening tools\nand removed medical record submission requirements.\n© 2025 UnitedHealthcare Services, Inc.\n9\n11/2017 Update to language in Genotype 1 criteria for treatment naïve\ncompensated cirrhotic patients.\n6/2019 Annual review. Added kidney transplant recipient section based on\nAASLD guidelines to allow for 12 weeks of therapy. Updated references.\n3/2020 Added requirement of Epclusa use for requests greater than 8 weeks.\nClarified kidney transplant criteria to align with current AASLD\nguidelines. Updated background and references.\n5/2021 Annual review. Removed prescriber requirement. Updated references.\n5/2022 Reformatted criteria. Updated references.\n5/2023 Annual review. Updated references.\n5/2024 Annual review. Removed liver disease staging criteria that was included\nfor quality purposes rather than part of coverage decision. Updated\nreferences.\n5/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n10"
  ]
}